Mike earned a PhD in Physiology from the Southern Illinois University in 1994 and has spent his entire scientific career in the pharmaceutical industry. He received his postdoctoral training in Neuroscience at Eli Lilly and Company, followed by a brief stint at Cadus Pharmaceutical identifying ligands to orphan GPCRs. In 1998 he returned to Eli Lilly and Company where he spent 20+ years working in the areas of Metabolic Disease and Neuroscience.
During his tenure at Lilly, Mike has led numerous small and large molecule projects from target identification, to lead optimization, to candidate selection, through clinical proof of concept. His work has resulted in several IND’s, patents and numerous peer reviewed publications.
In joining Recursion, Mike intends to deliver high value medicines for patients. He believes that Recursion’s novel technology will create opportunities to fundamentally change how new drugs
In his free time Mike enjoys spending time with friends and family mountain biking, hiking, kayaking and camping. He is an avid cook and advocates for locally sourced food.
Are you Recursion ready?
Join our passionate, innovative team—and help us realize our goal of 100 treatments by 2025.